IGM Biosciences IncNASDAQ:IGMS
- LAST PRICE14.2500
- TODAY'S CHANGE (%)-0.1500 (-1.0417%)
- Bid / Lots13.9800/ 3
- Ask / Lots14.2700/ 4
- Open / Previous Close14.1900 / 14.4000
- Day Range
- 52 Week Range
- Volume34,094
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IGMS |
|---|---|---|
| 09:32 ET | 2343 | 14.06 |
| 09:38 ET | 695 | 13.86 |
| 09:41 ET | 100 | 14.13 |
| 09:43 ET | 2035 | 14.4 |
| 09:45 ET | 100 | 14.4 |
| 09:48 ET | 200 | 14.32 |
| 09:50 ET | 100 | 14.32 |
| 09:52 ET | 100 | 14.41 |
| 09:54 ET | 233 | 14.4 |
| 09:56 ET | 100 | 14.42 |
| 09:57 ET | 400 | 14.42 |
| 09:59 ET | 100 | 14.43 |
| 10:03 ET | 1654 | 14.24 |
| 10:08 ET | 172 | 14.12 |
| 10:12 ET | 400 | 14.22 |
| 10:15 ET | 1828 | 13.91 |
| 10:19 ET | 100 | 13.99 |
| 10:24 ET | 263 | 13.975 |
| 10:26 ET | 316 | 13.975 |
| 10:32 ET | 100 | 14.13 |
| 10:33 ET | 600 | 14.145 |
| 10:35 ET | 1316 | 14 |
| 10:37 ET | 450 | 14.075 |
| 10:39 ET | 2476 | 14.1137 |
| 10:42 ET | 200 | 14.13 |
| 10:44 ET | 3833 | 14 |
| 10:50 ET | 1400 | 13.97 |
| 10:51 ET | 800 | 14.0799 |
| 10:53 ET | 100 | 13.975 |
| 10:55 ET | 459 | 14.075 |
| 10:57 ET | 200 | 14.06 |
| 11:02 ET | 100 | 14.06 |
| 11:04 ET | 100 | 14.055 |
| 11:13 ET | 100 | 14.11 |
| 11:15 ET | 1470 | 13.94 |
| 11:22 ET | 400 | 13.9745 |
| 11:24 ET | 500 | 14.17 |
| 11:26 ET | 100 | 14.25 |
| 11:29 ET | 100 | 14.25 |
Oct 1, 2024
DJ IGM Biosciences Is Maintained at Buy by Guggenheim, from 1:17PM ET on Tuesday Oct 01, 2024 by Dow Jones
1:17PM ET on Tuesday Oct 01, 2024 by Dow JonesDJ IGM Biosciences Is Maintained at Outperform by Wedbush, from 10:47AM ET on Tuesday Oct 01, 2024 by Dow Jones
10:47AM ET on Tuesday Oct 01, 2024 by Dow JonesDJ IGM Biosciences Is Maintained at Outperform by RBC Capital, from 10:35AM ET on Tuesday Oct 01, 2024 by Dow Jones
10:35AM ET on Tuesday Oct 01, 2024 by Dow JonesDJ IGM Biosciences Stock Drops Sharply on 'Pipeline Transformation' to Autoimmune Diseases -- Barrons.com, from 9:52AM ET on Tuesday Oct 01, 2024 by Dow Jones
9:52AM ET on Tuesday Oct 01, 2024 by Dow JonesDJ IGM Biosciences Cut to Underweight From Neutral by JP Morgan, from 9:22AM ET on Tuesday Oct 01, 2024 by Dow Jones
9:22AM ET on Tuesday Oct 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
IGM Biosciences Inc | 854.2M | -3.9x | --- |
Replimune Group Inc | 838.3M | -3.7x | --- |
Oruka Therapeutics Inc | 875.0M | -4.2x | --- |
Dianthus Therapeutics Inc | 821.3M | -5.1x | --- |
CARGO Therapeutics Inc | 827.7M | -5.1x | --- |
Perspective Therapeutics Inc | 890.7M | -9.5x | --- |
Company Information
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
Contact Information
- Headquarters
- 325 E Middlefield RdMOUNTAIN VIEW, CA, United States 94043-4003
- Phone
- 650-965-7873
- Fax
- 302-655-5049
Executives
- President, Chief Executive Officer, Director
- Fred Schwarzer
- Chief Financial Officer
- Misbah Tahir
- Chief Scientific Officer
- Bruce Keyt
- Chief Business Officer
- Lisa Decker
- Head - Research and Autoimmunity
- Mary Harler
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $854.2M |
|---|---|
Revenue (TTM) | $2.9M |
Shares Outstanding | 59.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.21 |
EPS | $-3.67 |
Book Value | $3.46 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | 293.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8,144.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
